Last reviewed · How we verify
Carboplatin MTD
Carboplatin MTD is a Small molecule drug developed by M.D. Anderson Cancer Center. It is currently in Phase 1 development. Also known as: Paraplatin.
Carboplatin is a small molecule DNA inhibitor used in the treatment of various conditions, including non-small cell lung carcinoma (NSCLC) and solid tumors. It is typically administered as part of a combination therapy, such as with paclitaxel, for the treatment of these conditions.
-
Baseline phase 1 → approval rate
+9.6pp
Industry-wide phase 1 drugs reach approval ~9.6% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2033–2036 | — |
| EMA | EU | 2034–2037 | +0.7 yr |
| MHRA | GB | 2034–2037 | +0.7 yr |
| Health Canada | CA | 2034–2038 | +0.9 yr |
| TGA | AU | 2034–2038 | +1.2 yr |
| PMDA | JP | 2034–2038 | +1.5 yr |
| NMPA | CN | 2035–2039 | +2.3 yr |
| MFDS | KR | 2034–2038 | +1.4 yr |
| CDSCO | IN | 2034–2039 | +1.8 yr |
| ANVISA | BR | 2035–2039 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Carboplatin MTD |
|---|---|
| Also known as | Paraplatin |
| Sponsor | M.D. Anderson Cancer Center |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
- Nausea
- Constipation
- Vomiting
- Diarrhea
- Mucositis
- Neutropenia
- Febrile neutropenia
- Thrombocytopenia
- Anemia
- AST
- ALT
- Hyperbilirubinemia
Key clinical trials
- A Phase I Open-Label, Single-Arm, Dose-Escalation Clinical and Pharmacology Study of CCI-001 as Monotherapy and in Combination With Standard Chemotherapy in Patients With Recurrent and/or Metastatic Solid Tumours (PHASE1)
- Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas (PHASE1)
- APG-115 in Salivary Gland Cancer Trial (PHASE1, PHASE2)
- Ascending Doses of Ceralasertib in Combination With Chemotherapy and/or Novel Anti Cancer Agents (PHASE1, PHASE2)
- Lattice-Based Radiotherapy and Chemo-Immunotherapy for Oral Cavity Squamous Cell Carcinoma (PHASE1)
- Study of Amivantamab, a Human Bispecific EGFR and cMet Antibody, in Participants With Advanced Non-Small Cell Lung Cancer (PHASE1)
- ZAP-IT: ZN-c3 + Carboplatin + Pembrolizumab in mTNBC (PHASE1, PHASE2)
- Gemcitabine, Carboplatin, and Lenalidomide for Treatment of Advanced/Metastatic Urothelial Cancer and Other Solid Tumors (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Carboplatin MTD CI brief — competitive landscape report
- Carboplatin MTD updates RSS · CI watch RSS
- M.D. Anderson Cancer Center portfolio CI
Frequently asked questions about Carboplatin MTD
What is Carboplatin MTD?
Who makes Carboplatin MTD?
Is Carboplatin MTD also known as anything else?
What development phase is Carboplatin MTD in?
What are the side effects of Carboplatin MTD?
Related
- Manufacturer: M.D. Anderson Cancer Center — full pipeline
- Also known as: Paraplatin
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing